The combination of CAR-T cells and nivolumab (anti-PD-1 antibody) has been used in the treatment of relapsed or refractory classical Hodgkin’s lymphoma (CHL) (63). This evidence concerns the gene PDCD1 and classic Hodgkin lymphoma.